Chengdu Suncadia opens dosing in first-in-human trial of HRS-1635 in B-cell cancers
The Phase 1 study will test dose-limiting toxicity across relapsed or refractory B-cell malignancies, with a 2028 primary completion date and no disclosed target for HRS-1635.
Executive Summary
- A first-in-human Phase 1 trial for HRS-1635 opened enrollment on schedule, moving from a planned to an active recruiting status in relapsed or refractory B-cell malignancies.
- The trial is built to find a tolerable dose and characterize side effects, not to show whether the drug works, with efficacy measures relegated to secondary endpoints collected over roughly two years.
- No competitor trial shares HRS-1635's target or mechanism in this disease setting, leaving the compound without a direct precedent to benchmark against as it enters the clinic.
- Chengdu Suncadia Medicine has completed every prior trial in its portfolio, a record that speaks to execution discipline rather than to how this specific compound will perform.
The status change
NCT07583212 updated its ClinicalTrials.gov record to Recruiting on July 13, 2026, replacing its prior Not yet recruiting status. The trial's start date moved from an anticipated June 1, 2026 to an actual June 30, 2026, and the registry now marks that start date as confirmed rather than projected. The trial targets 180 adult patients with histologically or cytologically confirmed relapsed or refractory B-cell malignant tumors, enrolled at sites in China. NCT07583212+1Phase I Study of HRS-1635 in B-cell MalignanciesNCT07583212Phase I Study of HRS-1635 in B-cell MalignanciesJul 13, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial will test
The primary endpoints are dose-limiting toxicity, assessed over roughly 23 days per cohort, and the incidence and severity of adverse events, tracked over approximately two years. Twelve secondary endpoints round out the design, including objective response rate, progression-free survival, overall survival, duration of response, and a full pharmacokinetic panel covering clearance, half-life, and exposure parameters. That structure is standard for a first-in-human oncology dose-escalation study: the trial exists to find a workable dose and confirm the regimen does not carry unacceptable toxicity, and any signal of clinical activity in the secondary measures is exploratory rather than decision-grade at this stage. NCT07583212Phase I Study of HRS-1635 in B-cell MalignanciesNCT07583212
Enrollment and protocol stability
The trial's enrollment target has not moved since its initial registry posting, holding at 180 patients across both submissions. Its registry history since first posting on May 13, 2026 shows two events: the initial study addition and the July 13 status change, with no amendments to eligibility criteria, endpoints, or the primary completion date. The primary completion date the sponsor has guided, October 1, 2028, falls within the trial's own stated window, and the study's overall completion date is set for December 1, 2029, giving a total planned duration of roughly 1,304 days from first patient in. NCT07583212Phase I Study of HRS-1635 in B-cell MalignanciesNCT07583212
Competitive and mechanistic context
HRS-1635's target and mechanism of action are not established in available records, so no first-in-class or differentiation claim can be made for the compound. The nearest trials in the same disease area target different biology altogether: a CD19-directed CAR-T therapy, CD19-UCART, is in testing for B-cell malignancy by EdiGene (GuangZhou) Inc., and the broader B-cell malignancy field includes approved and late-stage mechanisms such as CD19-targeted brexucabtagene autoleucel, the BCMA-directed agent elranatamab, and the BTK inhibitor zanubrutinib, none of which share a registry-confirmed target with HRS-1635. That leaves HRS-1635 without a direct comparator in this trial's competitive field as it enters human testing.
Sponsor execution
Chengdu Suncadia Medicine Co., Ltd. has completed all 12 of its prior trials globally with no terminations recorded, and currently runs three recruiting, three not-yet-recruiting, and two active-not-recruiting studies alongside HRS-1635. HRS-1635 is the sponsor's only registered trial in B-cell malignancy and its only clinical-stage program for this compound. That completion record reflects operational follow-through across the sponsor's broader pipeline; it says nothing about how HRS-1635 itself will perform in dose escalation. NCT07583212Phase I Study of HRS-1635 in B-cell MalignanciesNCT07583212
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.